Company / Shareholders' Equity
Janux Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$956.8M
FY2025
5-year range
$320.7M / $1.0B
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
#53 of 215
Health Care
What the data says
Janux Therapeutics, Inc.'s shareholders' equity of $957M is higher than 75% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 6 years, ranging from -$15M in FY2020 to $1.0B in FY2024.
Based on SEC 10-K filings.
$957M in FY2025 with a 3-year CAGR of +44.0%. Top quartile in the Health Care sector.
Improved from $344M to $957M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +44.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-62.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +44.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 6.4% year-over-year.
- Ranks #53 out of 215 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $956.8M | -6.4% |
| FY2024 | $1.0B | +197.0% |
| FY2023 | $344.3M | +7.4% |
| FY2022 | $320.7M | -12.4% |
| FY2021 | $366.3M | +2602.6% |
| FY2020 | -$14.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026